Dislosure

CME Matters presents…

Practical Management Strategies for the Metastatic Melanoma Patient: Applying the Evidence

Program Description
Evidence-based medicine is the new standard of care – something both patients and physicians demand. Accordingly, physicians and other healthcare providers must find ways to quickly become fluent in the latest clinical developments. By participating in Management Strategies for the Metastatic Melanoma Patient: Applying the Evidence, readers will have a more detailed understanding of key data from major melanoma clinical trials. In turn, participants will be better equipped to apply the evidence in the oncology practice setting.

Joint Sponsorship
This activity is jointly sponsored by the American Academy of CME (Academy) and North American Medical Education (NAME).

Disclosure Policy
It is the policy of the Academy to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of the Academy.

Disclosures
The faculty and planning committee for this activity reported the following:

John M. Kirkwood, MD
discloses that he is an Advisory Board member for scientific information for Pfizer, GlaxoSmithKline, and Schering-Plough Corporation. He is a consultant for clinical trial design for Intrexon, and Eleos. He is a member of the Schering-Plough Corporation promotional speakers’ bureau.

Planning Committee members, John JD Juchniewicz, MCIS, of American Academy of CME; Lisa Baez and Jacqueline Hernandez of North American Medical Education; and Anne Jacobson, MPH, Medical Writer, have no relevant financial disclosures to make.

Off-Label Disclosure Statement
The faculty has disclosed that this program will discuss either non-FDA-approved or investigational uses of the following agents/devices: anti-CTLA-4 antibodies, Hsp70 agonists, interferon, and melanoma vaccines.

Target Audience
This CME initiative is intended for dermatologists, medical and surgical oncologists, and other healthcare professionals involved in the long-term care of patients with melanoma.

Educational Objectives
• Describe major top-line findings from recent research in the use of immunotherapy and chemotherapy for metastatic melanoma

• Identify early signs of immune-related adverse effects in patients undergoing immunotherapy for metastatic melanoma

• List important prognostic factors in metastatic melanoma, and their role in treatment planning

• Describe promising research that may shape the future of immunotherapy in metastatic melanoma

Credit Availability
Release Date: 04/23/08
Expiration Date: 04/23/09

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME and North American Medical Education (NAME). The American Academy of CME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
American Academy of CME (Academy) designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Receiving Credit
The estimated time for the completion of this activity is one hour. To be eligible for CME credit, participants must review the activity and either a) log on to www.MelanomaCME.com for free online assessment and instant certification or b) complete and return the post-assessment questions and activity evaluation form found at the end of the transcript.

Commercial Supporter
This program is supported by an educational grant from Pfizer Inc.

Privacy Statement
This privacy statement explains our practices governing information obtained for continuing medical education courses.

Our Commitment to Privacy
The CME Matters and North American Medical Education (hereinafter "NAME") respects the privacy of every individual who visits http:// www.MelanomaCME.com (hereinafter the "CME site"). Because your privacy is important to us, we provide you with notice about the collection and use of your information. By visiting the NAME CME site, you accept the practices described in this privacy notice.

Data Collection
We collect two types of information:

Standard web server traffic pattern information. General traffic, site usage, and length of stay information is collected and stored in log files. This type of information may be shared externally only on an aggregated basis. We do not use cookies on our website.

Personal information. We do not collect personally identifiable information from you unless you provide it to us voluntarily and knowingly. The information you provide to our partner organizations in order to provide you with credit for completing the online medical education course, includes the following information: first and last name, street address, city, state, zip code, telephone number, area of practice, email address and other pertinent information. This information is collected on our online registration form.

If you choose to participate in other activities that are linked to this particular site, any information you provide will be protected in accordance with our general Online Privacy Policy, this includes requests for information.

Data Use
We limit the use of information provided to us on the CME site to the following:

We will only use aggregate information derived, in part, from your use of our site to improve our site and our service to you.

We will maintain records of the data you provide during registration.

Contact Us
By accessing or using the Web site, you agree to be bound by all of the terms and conditions of the NAME Privacy Policy as posted at the time of your access or use. If you have any questions about our privacy policy you may send us an email at info@namedu.com

For further information about this and other CME programs contact:
info@namedu.com or 561-265-3877

For CME Information or credit details contact:
psicora@academy.org or 609-921-6622

All rights reserved. None of the contents may be reproduced in any form without prior written permission from the Academy or NAME. The views and opinions expressed in this CME activity are those of the faculty and do not reflect the views of Pfizer Inc., or any other pharmaceutical company, the Academy, or NAME. The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used without evaluation of their patient’s conditions. Program participants are urged to consult the full prescribing information on any medication mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any agent.